Zenas BioPharma Added to NASDAQ Biotechnology Index: Key Takeaways
ByAinvest
Tuesday, Dec 23, 2025 6:14 am ET1min read
ZBIO--
Zenas BioPharma has been added to the NASDAQ Biotechnology Index. The company is a clinical-stage biopharmaceutical firm focused on immunology-based therapies for patients with autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit cells implicated in autoimmune diseases without depleting them. Zenas is developing obexelimab for several autoimmune diseases and has multiple programs in its pipeline, including ZB002, ZB004, ZB001, and ZB005.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet